Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

BACKGROUND: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Alfonso, Pilar, Chaves, Manuel, Muñoz, Andrés, Salud, Antonieta, García-Gonzalez, Maria, Grávalos, Cristina, Massuti, Bartomeu, González-Flores, Encarna, Queralt, Bernardo, López-Ladrón, Amelia, Losa, Ferran, Gómez, Maria Jose, Oltra, Amparo, Aranda, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423590/
https://www.ncbi.nlm.nih.gov/pubmed/25925749
http://dx.doi.org/10.1186/s12885-015-1293-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423590/
https://www.ncbi.nlm.nih.gov/pubmed/25925749
http://dx.doi.org/10.1186/s12885-015-1293-y

Ejemplares similares